precisionmedicineonline6h
Syndax's Revuforj Garners FDA Approval for Refractory KMT2A-Altered Acute Leukemia
NEW YORK – The US Food and Drug Administration on Friday approved Syndax Pharmaceuticals' Revuforj (revumenib) as a treatment for adult and pediatric patients one year and older with relapsed or ...
precisionmedicineonline10h
BRCA1/2 Mutations Aren't Equal: Researchers Push for Reduced Penetrance Pathogenic Variant Category
Researchers worked with two labs to identify 16 consensus lower-risk pathogenic variants and are pushing for greater ...
precisionmedicineonline12h
EMA's CHMP Recommends Approval for First-Line Opdivo-Yervoy in Certain Colorectal Cancers
Patients with MSI-high/dMMR advanced colorectal cancers had a 79 percent lower risk of disease progression or death on Opdivo-Yervoy compared to chemo.
precisionmedicineonline13h
Gilead Sciences to Lay Off 72 Employees, Shutter Seattle Office
January, come a year after the drugmaker slashed 7 percent of the workforce at Kite Pharma, its cell therapy business.
precisionmedicineonline13h
CHMP Recommends BMS's Augtyro for ROS1-Positive NSCLC, NTRK-Positive Tumors
The US Food and Drug Administration approved Augtyro in 2023 for the treatment of ROS1-positive advanced NSCLC. Earlier this year, the FDA also approved the drug for adult and pediatric patients 12 ...
precisionmedicineonline15h
Giostar Gearing up for Phase II Trial of Type 2 Diabetes Stem Cell Therapy in US
The FDA has cleared the research organization's investigational new drug application, allowing it to start clinical tests of the experimental treatment DT2-SCT.